These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15609297)

  • 1. Use of multiple biomarkers for a molecular diagnosis of prostate cancer.
    Landers KA; Burger MJ; Tebay MA; Purdie DM; Scells B; Samaratunga H; Lavin MF; Gardiner RA
    Int J Cancer; 2005 May; 114(6):950-6. PubMed ID: 15609297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression analysis of osteopontin mRNA splice variants in prostate cancer and benign prostatic hyperplasia.
    Tilli TM; Thuler LC; Matos AR; Coutinho-Camillo CM; Soares FA; da Silva EA; Neves AF; Goulart LR; Gimba ER
    Exp Mol Pathol; 2012 Feb; 92(1):13-9. PubMed ID: 21963599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.
    Klecka J; Holubec L; Pesta M; Topolcan O; Hora M; Eret V; Finek J; Chottova-Dvorakova M; Babjuk M; Novak K; Stolz J
    Anticancer Res; 2010 Feb; 30(2):665-70. PubMed ID: 20332487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
    Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
    Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DD3(PCA3) gene expression in cancer and prostatic hyperplasia.
    Floriano-Sánchez E; Cárdenas-Rodríguez N; Castro-Marín M; Alvarez-Grave P; Lara-Padilla E
    Clin Invest Med; 2009 Dec; 32(6):E258. PubMed ID: 20003831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
    Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
    Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
    Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
    Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
    Talesa VN; Antognelli C; Del Buono C; Stracci F; Serva MR; Cottini E; Mearini E
    Cancer Biomark; 2009; 5(6):241-51. PubMed ID: 20037200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis.
    Neves AF; Araújo TG; Biase WK; Meola J; Alcântara TM; Freitas DG; Goulart LR
    Clin Biochem; 2008 Oct; 41(14-15):1191-8. PubMed ID: 18640109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers.
    Mengual L; Ars E; Lozano JJ; Burset M; Izquierdo L; Ingelmo-Torres M; Gaya JM; Algaba F; Villavicencio H; Ribal MJ; Alcaraz A
    Actas Urol Esp; 2014 Apr; 38(3):143-9. PubMed ID: 24206626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
    Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
    Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
    Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
    Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
    Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
    Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer.
    Mearini E; Antognelli C; Del Buono C; Cochetti G; Giannantoni A; Nardelli E; Talesa VN
    Biomarkers; 2009 Jun; 14(4):235-43. PubMed ID: 19489685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction].
    Tao ZH; Mao XL; Wang CH; Chen XD; Yu KY; Weng ZL; Hu YP; Zhang XH; Xie H; Wang OC; Song QT; Li CD; Chen ZG
    Zhonghua Nan Ke Xue; 2007 Feb; 13(2):130-3. PubMed ID: 17345768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
    Guo J; Wang M; Wang Z; Liu X
    PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
    Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
    J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression analysis of delta-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer.
    Burger MJ; Tebay MA; Keith PA; Samaratunga HM; Clements J; Lavin MF; Gardiner RA
    Int J Cancer; 2002 Jul; 100(2):228-37. PubMed ID: 12115574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.